Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Early Proactive Therapeutic Drug Monitoring of Infliximab in Pediatric IBD
NCT05280405Phase 4Unknown
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in inflammatory bowel disease (IBD), sponsored by IRCCS Burlo Garofolo. Status: unknown.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05280405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280405.